Immunic, Inc. (NASDAQ:IMUX) Short Interest Up 14.9% in December

Immunic, Inc. (NASDAQ:IMUX) was the recipient of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 5,640,000 shares, a growth of 14.9% from the December 15th total of 4,910,000 shares. Based on an average trading volume of 976,100 shares, the short-interest ratio is currently 5.8 days.

Insider Activity at Immunic

In other Immunic news, Director Richard Alan Rudick purchased 87,300 shares of the firm’s stock in a transaction that occurred on Tuesday, November 12th. The shares were purchased at an average cost of $1.15 per share, for a total transaction of $100,395.00. Following the completion of the purchase, the director now directly owns 87,300 shares in the company, valued at $100,395. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 3.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Immunic

Institutional investors have recently made changes to their positions in the company. Virtu Financial LLC bought a new stake in shares of Immunic in the 3rd quarter valued at approximately $50,000. HB Wealth Management LLC bought a new position in Immunic during the 4th quarter worth $81,000. Jane Street Group LLC grew its stake in Immunic by 121.4% during the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after buying an additional 38,553 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its stake in Immunic by 70.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after buying an additional 42,383 shares during the last quarter. Finally, State Street Corp grew its stake in Immunic by 7.5% during the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after buying an additional 11,642 shares during the last quarter. 51.82% of the stock is currently owned by institutional investors.

Immunic Stock Down 3.4 %

Shares of IMUX traded down $0.03 during trading on Friday, reaching $0.95. The company’s stock had a trading volume of 1,720,429 shares, compared to its average volume of 781,842. The company has a fifty day moving average of $1.11 and a two-hundred day moving average of $1.31. Immunic has a twelve month low of $0.95 and a twelve month high of $2.11. The company has a market cap of $85.85 million, a price-to-earnings ratio of -0.77 and a beta of 1.88.

Analysts Set New Price Targets

A number of analysts recently commented on the company. HC Wainwright assumed coverage on Immunic in a research report on Monday, November 25th. They set a “buy” rating and a $10.00 price objective for the company. D. Boral Capital restated a “buy” rating and issued a $17.00 price target on shares of Immunic in a report on Tuesday, January 7th. Finally, StockNews.com cut Immunic from a “hold” rating to a “sell” rating in a report on Monday, November 11th. One research analyst has rated the stock with a sell rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Immunic has a consensus rating of “Buy” and a consensus target price of $12.67.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.